Bevacizumab Inhibits Angiogenic Cytokines in Head and Neck Squamous Cell Carcinoma: From Gene to the Protein
Background: Head and neck squamous cell carcinoma (HNSCC) is one most prevalent cancers among worldwide. Aim of this study was to evaluate possible effect of bevacizumab, a vascular endothelial growth (VEGF) factor monoclonal antibody on HNSCC cells in vitro to evaluate angiogenic profile changes. M...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2018-04-01
|
| Series: | International Journal of Hematology-Oncology and Stem Cell Research |
| Subjects: | |
| Online Access: | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/851 |
| _version_ | 1827843415332618240 |
|---|---|
| author | Hossein Heydar Kamran Mansouri Maryam Norooznezhad Fatemeh Norooznezhad Abdolreza Mohamadnia Naghmeh Bahrami |
| author_facet | Hossein Heydar Kamran Mansouri Maryam Norooznezhad Fatemeh Norooznezhad Abdolreza Mohamadnia Naghmeh Bahrami |
| author_sort | Hossein Heydar |
| collection | DOAJ |
| description | Background: Head and neck squamous cell carcinoma (HNSCC) is one most prevalent cancers among worldwide. Aim of this study was to evaluate possible effect of bevacizumab, a vascular endothelial growth (VEGF) factor monoclonal antibody on HNSCC cells in vitro to evaluate angiogenic profile changes.
Materials and Methods: HNSCC cells were grown and after that different concentrations of bevacizumab were added in order to evaluate cytotoxic concentration using MTT assay. Then after, the cultured cells in presence of different concentration of bevacizumab were evaluated for gene expression of VEGF, matrix metalloprotease-2 (MMP-2) and MMP-9 using real time polymerase chain reaction (PCR). Moreover, the VEGF expression was evaluated by enzyme-linked immunosorbent assay (ELISA).
Results: The concentration at which half cells died (IC59) was calculated 1779 µg/mL and at this concentration, VEGF protein secretion was decreased by over one fold. RT-PCR results showed that MMP2, MMP9 and VEGF decreased by 1, 0.6 and 1.1 folds, respectively.
Conclusion: It seems that bevacizumab could be considered as a side therapy for patients with HNSCC due to its potential for inhibition of angiogenic related factors, but further complementary studies are necessary. |
| first_indexed | 2024-03-12T08:25:31Z |
| format | Article |
| id | doaj.art-3204556dc63f43d48077848c1e9e3a18 |
| institution | Directory Open Access Journal |
| issn | 2008-2207 |
| language | English |
| last_indexed | 2024-03-12T08:25:31Z |
| publishDate | 2018-04-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | International Journal of Hematology-Oncology and Stem Cell Research |
| spelling | doaj.art-3204556dc63f43d48077848c1e9e3a182023-09-02T18:08:11ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-22072018-04-01122Bevacizumab Inhibits Angiogenic Cytokines in Head and Neck Squamous Cell Carcinoma: From Gene to the ProteinHossein Heydar0Kamran Mansouri1Maryam Norooznezhad2Fatemeh Norooznezhad3Abdolreza Mohamadnia4Naghmeh Bahrami5Craniomaxillofacial Research center, Tehran University of Medical Sciences, Oral and Maxillofacial Surgery Department, School of Dentistry, Tehran University of Medical Sciences, Tehran, IranMedical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, IranMedical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. AND Craniomaxillofacial Research center, Tehran University of Medical Sciences, Oral and Maxillofacial Surgery Department, School of Dentistry, Tehran University of Medical Sciences, Tehran, IranMedical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, IranVirology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. AND Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranCraniomaxillofacial Research center, Tehran University of Medical Sciences, Oral and Maxillofacial Surgery Department, School of Dentistry, Tehran University of Medical Sciences, Tehran, IranBackground: Head and neck squamous cell carcinoma (HNSCC) is one most prevalent cancers among worldwide. Aim of this study was to evaluate possible effect of bevacizumab, a vascular endothelial growth (VEGF) factor monoclonal antibody on HNSCC cells in vitro to evaluate angiogenic profile changes. Materials and Methods: HNSCC cells were grown and after that different concentrations of bevacizumab were added in order to evaluate cytotoxic concentration using MTT assay. Then after, the cultured cells in presence of different concentration of bevacizumab were evaluated for gene expression of VEGF, matrix metalloprotease-2 (MMP-2) and MMP-9 using real time polymerase chain reaction (PCR). Moreover, the VEGF expression was evaluated by enzyme-linked immunosorbent assay (ELISA). Results: The concentration at which half cells died (IC59) was calculated 1779 µg/mL and at this concentration, VEGF protein secretion was decreased by over one fold. RT-PCR results showed that MMP2, MMP9 and VEGF decreased by 1, 0.6 and 1.1 folds, respectively. Conclusion: It seems that bevacizumab could be considered as a side therapy for patients with HNSCC due to its potential for inhibition of angiogenic related factors, but further complementary studies are necessary.https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/851Head and neck squamous cell carcinomaBevacizumabAngiogenesisVascular endothelial growthMatrix metalloproteases |
| spellingShingle | Hossein Heydar Kamran Mansouri Maryam Norooznezhad Fatemeh Norooznezhad Abdolreza Mohamadnia Naghmeh Bahrami Bevacizumab Inhibits Angiogenic Cytokines in Head and Neck Squamous Cell Carcinoma: From Gene to the Protein International Journal of Hematology-Oncology and Stem Cell Research Head and neck squamous cell carcinoma Bevacizumab Angiogenesis Vascular endothelial growth Matrix metalloproteases |
| title | Bevacizumab Inhibits Angiogenic Cytokines in Head and Neck Squamous Cell Carcinoma: From Gene to the Protein |
| title_full | Bevacizumab Inhibits Angiogenic Cytokines in Head and Neck Squamous Cell Carcinoma: From Gene to the Protein |
| title_fullStr | Bevacizumab Inhibits Angiogenic Cytokines in Head and Neck Squamous Cell Carcinoma: From Gene to the Protein |
| title_full_unstemmed | Bevacizumab Inhibits Angiogenic Cytokines in Head and Neck Squamous Cell Carcinoma: From Gene to the Protein |
| title_short | Bevacizumab Inhibits Angiogenic Cytokines in Head and Neck Squamous Cell Carcinoma: From Gene to the Protein |
| title_sort | bevacizumab inhibits angiogenic cytokines in head and neck squamous cell carcinoma from gene to the protein |
| topic | Head and neck squamous cell carcinoma Bevacizumab Angiogenesis Vascular endothelial growth Matrix metalloproteases |
| url | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/851 |
| work_keys_str_mv | AT hosseinheydar bevacizumabinhibitsangiogeniccytokinesinheadandnecksquamouscellcarcinomafromgenetotheprotein AT kamranmansouri bevacizumabinhibitsangiogeniccytokinesinheadandnecksquamouscellcarcinomafromgenetotheprotein AT maryamnorooznezhad bevacizumabinhibitsangiogeniccytokinesinheadandnecksquamouscellcarcinomafromgenetotheprotein AT fatemehnorooznezhad bevacizumabinhibitsangiogeniccytokinesinheadandnecksquamouscellcarcinomafromgenetotheprotein AT abdolrezamohamadnia bevacizumabinhibitsangiogeniccytokinesinheadandnecksquamouscellcarcinomafromgenetotheprotein AT naghmehbahrami bevacizumabinhibitsangiogeniccytokinesinheadandnecksquamouscellcarcinomafromgenetotheprotein |